You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


MHRA deems Sanofi’s avalglucosidase alfa ‘promising’ for Pompe disease

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has issued Sanofi a Promising Innovative Medicine (PIM) designation for avalglucosidase alfa in the treatment of Pompe disease.